Physician profile
Sanjeev Singh
NPI 1316905797
$11,431.12
in general payments reported to CMS, 2019-2025
34 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,918 · 2020: $926 · 2021: $889 · 2022: $882 · 2023: $1,905 · 2024: $2,679 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,920.32 | 2019-2024 | Spravato |
| Abbvie INC. | $2,468.65 | 2021-2024 | Vraylar |
| Neuronetics, INC. | $916.12 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $368.67 | 2019-2024 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $327.53 | 2023-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $310.87 | 2019-2022 | |
| Alkermes, INC. | $302.53 | 2019-2025 | Lybalvi, Aristada |
| Corium, LLC | $261.61 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $254.52 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $252.56 | 2019-2024 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $246.34 | 2020-2024 | Austedo Xr, Uzedy, Austedo |
| Bausch Health US, LLC | $183.91 | 2020-2025 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $158.24 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $143.72 | 2020-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.89 | 2021-2024 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $131.82 | 2022-2024 | Dyanavel Xr |
| Neos Therapeutics, Lp | $127.18 | 2019-2024 | Adzenys Xr-Odt |
| Eisai INC. | $124.03 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $119.84 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $105.62 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $95.97 | 2020-2022 | |
| Validus Pharmaceuticals LLC | $83.16 | 2019-2023 | Equetro |
| Bioxcel Therapeutics, INC. | $63.11 | 2023 | Igalmi |
| Adlon Therapeutics L.P. | $62.53 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $56.10 | 2023 | Quviviq |
| Almatica Pharma LLC | $43.03 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $36.97 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $31.18 | 2021-2022 | |
| Noven Therapeutics, LLC | $23.37 | 2024 | Xelstrym |
| Owp Pharmaceuticals, INC. | $19.44 | 2021 | |
| Supernus Pharmaceuticals, INC. | $16.81 | 2023 | Qelbree |
| Shire North American Group INC | $15.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.30 | 2020 | |
| Alfasigma USA, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.